Navigation Links
InterMune Initiates Phase 3 ASCEND Study of Pirfenidone in IPF
Date:7/7/2011

BRISBANE, Calif., July 7, 2011 /PRNewswire/ -- InterMune (NASDAQ: ITMN) today announced that patient enrollment has begun in ASCEND, a new Phase 3 study of pirfenidone for patients who suffer from idiopathic pulmonary fibrosis (IPF).  ASCEND is a multinational, randomized, double-blind, placebo controlled Phase 3 trial designed to evaluate the safety and efficacy of Esbriet® (pirfenidone) in IPF patients with mild to moderate impairment in lung function.  The primary endpoint is lung function, as measured by change in forced vital capacity (FVC) from baseline to Week 52.  The trial will enroll a total of approximately 500 patients who will be randomly assigned 1 to 1 to receive oral pirfenidone (2403 mg/day) or placebo.  Patients will be enrolled at centers in the United States, Mexico, South America, Australia and New Zealand.  

Steve Porter, M.D., Ph.D., Chief Medical Officer of InterMune, said, "We are very pleased to report enrollment of the first patient in ASCEND.  This study represents our continued commitment to making Esbriet available for the more than 100,000 IPF patients in the United States who are afflicted with IPF but currently have no FDA-approved therapies available to them."  

ASCEND Phase 3 Trial

InterMune's new Phase 3 study of pirfenidone is named ASCEND (Assessment of Pirfenidone to Confirm Efficacy and Safety in IPF).  ASCEND will add to pirfenidone's body of clinical evidence and support a future submission for FDA approval.

InterMune expects the trial to be fully enrolled by the first half of 2012, and that results from the study will be available in mid-2013.  InterMune anticipates a New Drug Application (NDA) resubmission for pirfenidone in the second half of 2013 and an FDA action in the first half of 2014.  

Relative to InterMune's previous studies o
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. InterMune to Present at Canaccord Adams Conference
2. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
3. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
4. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
5. InterMune to Release Third Quarter 2008 Financial Results on November 6
6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
7. InterMune to Present at Deutsche Bank Biotech Boston Confab
8. InterMune to Present at J.P. Morgan Healthcare Conference
9. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
10. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... , April 20, 2015 PointCross Life ... Ltd. to provide an integrated Big Data and globally ... biomarkers collected in the context of clinical trials and ... precise or multi-targeted drug candidates, stratified patient selection and ... progression free survival. Highlighting the timing ...
(Date:4/20/2015)... ANGELES , April 20, 2015  "Everybody is ... we do to patients is frankly brutal. We,ve got ... in a cancer ward, or witnessed a loved one ... you,ve witnessed firsthand the devastation chemotherapy and other treatments ... most people want to give up and succumb to ...
(Date:4/20/2015)... 2015 /CNW/ - Portage Biotech Inc. ("Portage" or "the ... pleased to announce that its wholly owned subsidiary, Portage ... that showed one of its proprietary human-derived CPP sequences ... through inhibition of NFkB signalling even if administered when ... of the blood brain barrier (BBB) in mice was ...
(Date:4/20/2015)... 20, 2015   Meditope Biosciences, Inc ., a ... technology, today announced presentation of data demonstrating the use ... antibody-drug conjugates (ADCs). The data were presented in an abstract ... 18-22 in Philadelphia . ... point to the many commercial applications that may be ...
Breaking Biology Technology:PointCross Life Sciences and InterpretOmics partner for Clinical and Genomic Biomarker Management for Drug Development 2Is Dr. Craig Dionne the Steve Jobs of Cancer Research? 2Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 2Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 3Meditope Biosciences Presents Data At The American Association Of Cancer Research (AACR) Annual Meeting Validating Its SnAP Technology Platform 2
... (Nasdaq: ERES ) announced today that it will ... 2010 Tuesday, March 1, after the market closes. After the ... PM ET that day. For the conference ... United States or 1-412-858-4600 when calling internationally. There will be ...
... Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today ... BIO CEO & Investor Conference on Monday, February 14, ... the Waldorf=Astoria Hotel in New York City. Jack Lief, Arena,s President ... A live audio webcast of the presentation will be ...
... Stem Cell Assurance, Inc. (Pink Sheets: SCLZ) ... its financial statements as of December 31, 2009 and 2010 ... "Top 25 Firms" by Inside Public Accounting , Marcum ... than 150 partners, in 23 offices throughout New York, New ...
Cached Biology Technology:ERT Reports Fourth Quarter and Full Year 2010 Operating Results on March 1, 2011 2Arena Pharmaceuticals to Present at the 13th Annual BIO CEO & Investor Conference 2Arena Pharmaceuticals to Present at the 13th Annual BIO CEO & Investor Conference 3Stem Cell Assurance Announces Engagement of Marcum LLP as its Independent Auditors 2
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
(Date:3/20/2015)... 20, 2015 Research and Markets ... the "India Sensors Market Forecast and Opportunities ... The sensor market is projected to grow at ... Consumer electronics, automotive, industrial and healthcare sectors are ... country. In addition, adoption of MEMS technology in ...
(Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... wallet is one of the products featured in 2015 ... 20th at 11:00 PM EST on the DIY Network. ... Las Vegas , site of the ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... Energy Secretary Steven Chu announced today that more than ... and Reinvestment Act will go toward scientific research, instrumentation, ... in six states will be receiving funds, along with ... "These new initiatives will help to create ...
... antibiotic drought, scientists in Massachusetts are describing successful use ... to discover badly needed new antibiotics. Their study appeared ... Frederick Ausubel and colleagues note in the ... involve adding the potential drug to cultures of bacteria ...
... the world,s environment ministers, government officials, diplomats and campaigners ... December 2009 to unite in the battle against climate ... the world has ever seen, the increasingly complex territory ... published today, 5 August, 2009, in IOP Publishing,s ...
Cached Biology News:Obama administration announces more than $327 million in Recovery Act funding for science research 2Obama administration announces more than $327 million in Recovery Act funding for science research 3Climate change poker: The barriers which are preventing a global agreement 2
...
... Ideal for relax positively and negatively supercoiled ... , Studying the effects of supercoiling ... reconstitution in vitro , Determining the degree ... Detecting mutant plasmids that differ in length by ...
ssDNA from PCR DNA in less than 1 hour. No gels, columns, or slurries. Sequence from high quality ssDNA: clearer reads, longer runs....
Immunogen: Synthetic peptide (KLH conjugated): L(506) S K S S S Q I R M S G L P A D N L A T(525) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: